>>Signaling Pathways>> Chromatin/Epigenetics>> Histone Methyltransferase>>SETDB1-TTD-IN-1

SETDB1-TTD-IN-1

Catalog No.GC64893

SETDB1-TTD-IN-1은 Kd가 88nM인 SET 도메인 분기 단백질 1 탠덤 튜더 도메인(SETDB1-TTD)의 강력하고 선택적인 내인성 결합제 경쟁 억제제입니다. SETDB1-TTD-IN-1은 SETDB1-TTD의 생물학적 기능 및 질병 연관성 연구에 사용할 수 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

SETDB1-TTD-IN-1 Chemical Structure

Cas No.: 2755823-12-0

Size 가격 재고 수량
5 mg
US$738.00
재고 있음
10 mg
US$1,188.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

SETDB1-TTD-IN-1 is a potent, selective and endogenous binder competitive inhibitor of SET domain bifurcated protein 1 tandem tudor domain (SETDB1-TTD), with a Kd of 88 nM. SETDB1-TTD-IN-1 can be used for the research of biological functions and disease associations of SETDB1-TTD[1].

SETDB1-TTD-IN-1 shows some activity for 53BP1 and JMJD2A, with Kds of 4.3 μM and 86 μM, respectively. SETDB1-TTD-IN-1 does not show activity against 14 of the 16 tested tudor domains (Kd>100 μM)[1].SETDB1-TTD-IN-1 (2.5-40 μM) efficiently and dose-dependently stabilizes the SETDB1-TTD protein in HEK293T cells[1].SETDB1-TTD-IN-1 (2.5-40 μM; 24 h) significantly affected the expression of 72 genes in human acute monocytic leukemia THP-1 cells[1].

[1]. Guo Y, et, al. Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain. Angew Chem Int Ed Engl. 2021 Apr 12;60(16):8760-8765.

리뷰

Review for SETDB1-TTD-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SETDB1-TTD-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.